Transplantation of microencapsulated umbilical-cord-blood-derived hepatic-like cells for treatment of hepatic failure

Figure 1 FACS determination of CD34⁺ cells. A: Purity of CD34⁺ cells; B: Homotypic control cells.

Figure 2 Cell culture and analyses. A: After 16 d; B: A binucleated cell; C, D: Positive staining for albumin (C) and α-fetoprotein (D) after 16 d of indction.

Figure 3 Reverse transcription-polymerase chain reaction analysis of umbilical cord blood CD34⁺ cells cultured in vitro d 0, d 8 and d 16. ALB: Albumin; AFP: α-fetoprotein.

Figure 4 Determination of albumin expression by Enzyme-Linked Immunosorbent Assay. ALB: Albumin.

Figure 5 Pathological changes in the livers of acute hepatic failure rats. A: Liver at 48 h after injection of D-galactosamine; B: Liver at 48 h after microcapsule transplantation; C: HE staining of the liver shown in section (A); D: HE staining of the liver shown in section (B).

Figure 6 Encapsules observation. A: Microcapsules created by the Alginate-poly-l-lysine-alginate microencapsulation method; B: Microcapsule masses in the peritoneal lavage fluid; C: Free microcapsules in the peritoneal lavage fluid; D: HE staining shows microcapsules in the greater omentum.